Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Data from Cyclin D1 and Cdk4 Mediate Development of Neurologically Destructive Oligodendroglioma

View through CrossRef
<div>Abstract<p>Although the molecular changes that characterize gliomas have been studied, the pathogenesis of tumor development remains unclear. p21 contributes to gliomagenesis by stabilizing cyclin D1–cdk4 kinase complexes, suggesting that cyclin D1 and cdk4 may also be required for glial tumor development. In this study, we used a mouse model to attempt to confirm this hypothesis, finding that cyclin D1 and cdk4 played active roles in not only the tumor but also the tumor microenvironment. Loss of cdk4 blocked tumor development, but loss of cyclin D1 did not prevent gliomas from developing. Instead, loss of cyclin D1 impeded progression to higher stages of malignancy. Enforcing expression of cyclin D1 was insufficient to correct the progression defect observed in cyclin D1–deficient animals. In contrast, restoration of cdk4 in the cdk4-deficient animals restored cell proliferation and tumor formation, although at lower tumor grades. Notably, the failure of tumors in the cyclin D1- and cdk4-deficient animals to progress to higher grades was correlated with a failure to fully activate microglia in the tumor microenvironment. Moreover, when platelet-derived growth factor–transformed glial cells were engrafted orthotopically into the mice, the tumors that formed progressed to high grades in wild-type mice but not cyclin D1–deficient animals. Together, our findings establish that the cyclin D1–cdk4 axis is not only critical in glial tumor cells but also in stromal-derived cells in the surrounding tumor microenvironment that are vital to sustain tumor outgrowth. <i>Cancer Res; 71(19); 6174–83. ©2011 AACR</i>.</p></div>
Title: Data from Cyclin D1 and Cdk4 Mediate Development of Neurologically Destructive Oligodendroglioma
Description:
<div>Abstract<p>Although the molecular changes that characterize gliomas have been studied, the pathogenesis of tumor development remains unclear.
p21 contributes to gliomagenesis by stabilizing cyclin D1–cdk4 kinase complexes, suggesting that cyclin D1 and cdk4 may also be required for glial tumor development.
In this study, we used a mouse model to attempt to confirm this hypothesis, finding that cyclin D1 and cdk4 played active roles in not only the tumor but also the tumor microenvironment.
Loss of cdk4 blocked tumor development, but loss of cyclin D1 did not prevent gliomas from developing.
Instead, loss of cyclin D1 impeded progression to higher stages of malignancy.
Enforcing expression of cyclin D1 was insufficient to correct the progression defect observed in cyclin D1–deficient animals.
In contrast, restoration of cdk4 in the cdk4-deficient animals restored cell proliferation and tumor formation, although at lower tumor grades.
Notably, the failure of tumors in the cyclin D1- and cdk4-deficient animals to progress to higher grades was correlated with a failure to fully activate microglia in the tumor microenvironment.
Moreover, when platelet-derived growth factor–transformed glial cells were engrafted orthotopically into the mice, the tumors that formed progressed to high grades in wild-type mice but not cyclin D1–deficient animals.
Together, our findings establish that the cyclin D1–cdk4 axis is not only critical in glial tumor cells but also in stromal-derived cells in the surrounding tumor microenvironment that are vital to sustain tumor outgrowth.
<i>Cancer Res; 71(19); 6174–83.
©2011 AACR</i>.
</p></div>.

Related Results

Abstract P6-07-02: CDK4 phosphorylation status and corresponding gene expression profile predict sensitivity to Palbociclib
Abstract P6-07-02: CDK4 phosphorylation status and corresponding gene expression profile predict sensitivity to Palbociclib
Abstract Although the specific CDK4/6 inhibitor PD0332991 (Palbociclib) was recently approved by the FDA to treat advanced ER+ breast tumors, there is yet no reliabl...
Abstract P4-11-02: Characterization of BTX-9341, a bifunctional degrader of CDK4 and CDK6 for HR+/HER2- breast cancer
Abstract P4-11-02: Characterization of BTX-9341, a bifunctional degrader of CDK4 and CDK6 for HR+/HER2- breast cancer
Abstract CDK4/6 inhibitors (CDK4/6i) such as palbociclib, abemaciclib and ribociclib are used to treat HR+/HER2- breast cancer, but patients can develop resistance v...
Abstract PO5-05-02: Discovery of BTX-9341, a bifunctional degrader of CDK4 and CDK6 for HR+/HER2- breast cancer
Abstract PO5-05-02: Discovery of BTX-9341, a bifunctional degrader of CDK4 and CDK6 for HR+/HER2- breast cancer
Abstract CDK4/6 inhibitors (CDK4/6i) such as palbociclib, abemaciclib and ribociclib are used to treat HR+/HER2- breast cancer, but patients can develop resistance v...
Data from Cyclin D1 and Cdk4 Mediate Development of Neurologically Destructive Oligodendroglioma
Data from Cyclin D1 and Cdk4 Mediate Development of Neurologically Destructive Oligodendroglioma
<div>Abstract<p>Although the molecular changes that characterize gliomas have been studied, the pathogenesis of tumor development remains unclear. p21 contributes to gl...
Characterization of BTX-9341, a bifunctional degrader of CDK4 and CDK6 for HR+/HER2- breast cancer and glioblastoma multiforme.
Characterization of BTX-9341, a bifunctional degrader of CDK4 and CDK6 for HR+/HER2- breast cancer and glioblastoma multiforme.
3111 Background: CDK4/6 inhibitors (CDK4/6i) are used to treat HR+/HER2- breast cancer, but patients develop resistance via many mechanisms, many of which involve on the upregulat...
Abstract 6068: Discovery of BTX-9341, a bifunctional degrader of CDK4 and CDK6 for HR+/HER2- breast cancer
Abstract 6068: Discovery of BTX-9341, a bifunctional degrader of CDK4 and CDK6 for HR+/HER2- breast cancer
Abstract CDK4/6 inhibitors (CDK4/6i) such as palbociclib, abemaciclib and ribociclib are used to treat HR+/HER2- breast cancer, but patients can develop resistance v...
Abstract 5814: Emergent functions of cyclin-dependent kinase 4 regulating aurora b and cenpp transcription
Abstract 5814: Emergent functions of cyclin-dependent kinase 4 regulating aurora b and cenpp transcription
Abstract A better understanding of the precise molecular mechanisms that control cell proliferation is crucial for the identification of novel cancer therapeutic tar...

Back to Top